Announcements

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our selected papers related to cancer causes, screening and diagnosis in 2024, which are listed below:

1. “Risk Factors and Innovations in Risk Assessment for Melanoma, Basal Cell Carcinoma, and Squamous Cell Carcinoma”
by K. Wunderlich, M. Suppa, S. Gandini, J. Lipski, J. M. White and V. Del Marmol
Cancers 2024, 16(5), 1016; https://doi.org/10.3390/cancers16051016
Available online: https://www.mdpi.com/2072-6694/16/5/1016

2. “Emerging Trends in AI and Radiomics for Bladder, Kidney, and Prostate Cancer: A Critical Review”
by Georgios Feretzakis, Patrick Juliebø-Jones, Arman Tsaturyan, Tarik Emre Sener, Vassilios S. Verykios, Dimitrios Karapiperis, Themistoklis Bellos, Stamatios Katsimperis, Panagiotis Angelopoulos, Ioannis Varkarakis et al.
Cancers, 2024, 16(4), 810; https://doi.org/10.3390/cancers16040810
Available online: https://www.mdpi.com/2072-6694/16/4/810

3. “Novelty Classification Model Use in Reinforcement Learning for Cervical Cancer”
by Shakhnoza Muksimova, Sabina Umirzakova, Khusanboy Shoraimov, Jushkin Baltayev and Young-Im Cho
Cancers 2024, 16(22), 3782; https://doi.org/10.3390/cancers16223782
Available online: https://www.mdpi.com/2072-6694/16/22/3782

4. “Exploring the Potential Link between PFAS Exposure and Endometrial Cancer: A Review of Environmental and Sociodemographic Factors”
by Aderonke Ayodele and Emmanuel Obeng-Gyasi
Cancers 2024, 16(5), 983; https://doi.org/10.3390/cancers16050983
Available online: https://www.mdpi.com/2072-6694/16/5/983

5. “Imaging Recommendations for Diagnosis and Management of Primary Parathyroid Pathologies: A Comprehensive Review”
by Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu and Anil K. D’Cruz
Cancers 2024, 16(14), 2593; https://doi.org/10.3390/cancers16142593
Available online: https://www.mdpi.com/2072-6694/16/14/2593

6. “The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)”
by Daniela Fischerova, Filip Frühauf, Andrea Burgetova, Ingfrid S. Haldorsen, Elena Gatti and David Cibula
Cancers 2024, 16(4), 775; https://doi.org/10.3390/cancers16040775
Available online: https://www.mdpi.com/2072-6694/16/4/775

7. “Endometrial Cancer: 2023 Revised FIGO Staging System and the Role of Imaging”
by Manuel Menendez-Santos, Carlos Gonzalez-Baerga, Daoud Taher, Rebecca Waters, Mayur Virarkar and Priya Bhosale
Cancers 2024, 16(10), 1869; https://doi.org/10.3390/cancers16101869
Available online: https://www.mdpi.com/2072-6694/16/10/1869

8. “Non-Invasive Markers for the Detection of Gastric Precancerous Conditions”
by Marcin Romańczyk, Malgorzata Osmola, Alexander Link, Amaury Druet, Caroline Hémont, Jerome Martin, Nicolas Chapelle and Tamara Matysiak-Budnik
Cancers 2024, 16(12), 2254; https://doi.org/10.3390/cancers16122254
Available online: https://www.mdpi.com/2072-6694/16/12/2254

9. “Artificial-Intelligence-Assisted Detection of Metastatic Colorectal Cancer Cells in Ascitic Fluid”
by Hyung Kyung Kim, Eunkyung Han, Jeonghyo Lee, Kwangil Yim, Jamshid Abdul-Ghafar, Kyung Jin Seo, Jang Won Seo, Gyungyub Gong, Nam Hoon Cho, Milim Kim et al.
Cancers 2024, 16(5), 1064; https://doi.org/10.3390/cancers16051064
Available online: https://www.mdpi.com/2072-6694/16/5/1064

10. “Artificial Intelligence in Urologic Robotic Oncologic Surgery: A Narrative Review”
by Themistoklis Bellos, Ioannis Manolitsis, Stamatios Katsimperis, Patrick Juliebø-Jones, Georgios Feretzakis, Iraklis Mitsogiannis, Ioannis Varkarakis, Bhaskar K. Somani and Lazaros Tzelves
Cancers 2024, 16(9), 1775; https://doi.org/10.3390/cancers16091775
Available online: https://www.mdpi.com/2072-6694/16/9/1775

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

At MDPI, we recognize that peer review is the cornerstone of scientific progress. The integrity and quality of our journals rely on the careful evaluations of our reviewers. In 2024, more than 215,000 reviewers submitted over 1.2 million reports—a testament to the strength of our community.

The MDPI Reviewer Club series was created to honor this vital work and provide a forum for sharing experiences, best practices, and building meaningful connections across disciplines.

We are delighted to invite you to the upcoming webinar: “MDPI Reviewer Club 2025 | Public Health and Medicine Session”.

This session is dedicated to bringing together reviewers in the subjects of public health and medicine to exchange insights and celebrate their role in advancing scholarly publishing.

Session highlights:

• From Bench to Publication: Strengthening Biological Science Manuscripts Through Peer Review;
• The Role of Peer Review in Nursing Science: Elevating Manuscript Quality Through Critical Insight.

With speakers’ consent, presentations will be recorded and shared on MDPI platforms to encourage continued discussion.

This marks the only session of the MDPI Reviewer Club 2025 in the subjects of public health and medicine. Each session offers fresh perspectives, cross-disciplinary learning, and a platform to celebrate our reviewers’ invaluable contributions.

We warmly welcome you to join us for this inspiring exchange at the MDPI Reviewer Club 2025 | Public Health and Medicine Session.

Keywords: peer review; public health; clinical medicine; nursing science; biological sciences; manuscript quality; research integrity; publication process; reviewer insights

Date: 18 September 2025 | 6:30 p.m. CEST | 12:30 p.m. EST |
Webinar ID: 852 6635 8176
Website: https://sciforum.net/event/MRC2025-PHM

Register now for free!

Program:

After registering, you will receive a confirmation email with information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.

Unable to attend? Register anyway, and we will let you know when the recording is available for viewing.

Webinar Speakers:

• Subhadeep Das, Department of Biochemistry, Purdue University, Indiana, USA;
• Wendy L. Sarver, Interim Graduate Program Coordinator, Cleveland State University, Cleveland, USA.

We congratulate Dr. Luca Tiraboschi for winning the Cancers 2025 Best PhD Thesis Award with his publication, “Impact of Intratumoral Microbiota in Soft Tissue Sarcoma Treatment Efficacy”. 

Name: Dr. Luca Tiraboschi
Affiliation: IRCCS Humanitas Research Hospital, 20089 Milan, Italy
Research interests: translational research; osteosarcoma; dog; cancer vaccine 

The following is an interview with Dr. Luca Tiraboschi: 

1. Could you tell us a little bit about yourself and the scientific research you conducted during your doctoral studies?
During my PhD, I focused on exploring the interactions between cancer and microbiota. My thesis included two main projects. The first investigated the role of the intratumoral microbiome in soft tissue sarcomas and its ability to inactivate the chemotherapeutic drug doxorubicin, potentially contributing to treatment resistance. The second project aimed to develop an innovative antitumor vaccine based on ER stress-derived peptides, designed to enhance the immune response and possibly overcome resistance to immune checkpoint inhibitors. Overall, my doctoral work combined microbiology, immunology, and oncology, with the broader goal of identifying novel therapeutic strategies for cancer patients. 

2. Did you encounter any difficulties in carrying out this research? If yes, how did you overcome them, and what strategies did you use to stay focused and motivated?
Like most research projects, mine came with challenges both technical and conceptual. Isolating and characterizing tumor-resident bacteria, for example, required the optimization of protocols that were not well established in the field. At times, progress was slower than expected, which was frustrating. What helped me was keeping a clear long-term vision, breaking down big goals into smaller, achievable steps, and relying on the support of my colleagues and mentors. Staying motivated also meant reminding myself of the potential impact my research could have on patients’ lives, which kept me focused during difficult moments. 

3. As an author, what aspects of a journal do you value the most when choosing a journal in which to publish your academic work?
When selecting a journal, I value scientific rigor, transparency in the peer-review process, and a readership that aligns with the scope of my research. I also appreciate journals that foster open access and broad dissemination, making scientific discoveries more widely available to both researchers and clinicians. Additionally, a constructive and fair review process is crucial, as it contributes to improving the quality and clarity of the final manuscript. 

4. What is your current research interest, and how do you plan to continue building on your research in the future? What are your long-term career aspirations?
Currently, I am continuing to investigate the role of the tumor-associated microbiome in modulating the efficacy of cancer therapies, with a focus on chemotherapy and immunotherapy. I aim to integrate microbiology, genomics, and immunology to identify microbiome-based biomarkers and therapeutic strategies that could be translated into clinical applications. In the long term, my aspiration is to build an independent research program at the intersection of oncology and microbiome science, contributing to precision medicine approaches that improve treatment outcomes for cancer patients. 

We congratulate Dr. Filipa Martins for winning the Cancers 2025 Best PhD Thesis Award with her publication, “Targeting Glutamine Availability – A New Strategy To Treat Malignant Gliomas”.

Name: Dr. Filipa Martins
Affiliation: iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal
Research interests: malignant gliomas; glutamine-glutamate cycle; CNS; cancer metabolism; metabolic adaptation; new metabolic-driven targets; neo-angiogenesis; anti-angiogenic therapy; Cancer Therapy; VEGF; new targets; drug resistance

The following is an interview with Dr. Filipa Martins:

1. Could you tell us a little bit about yourself and the scientific research you conducted during your doctoral studies?

I have always been fascinated by the biology of cancer, and my academic background in biochemistry and molecular biology naturally led me to pursue a PhD in health sciences. Previously, I investigated cancer-associated angiogenesis and oxidative stress, but during my doctoral studies, my focus shifted towards cancer metabolism.

My PhD research centered on understanding how glioblastoma (GBM) cells reprogram their metabolic pathways to sustain growth. In particular, we explored the glutamine dependency of GBM, given the altered metabolic networks and preferential carbon source utilization observed in these cells. Based on these insights, we developed two glutamine metabolism-targeted therapies for GBM: a systemic glutaminase (GLS1) treatment that offers a non-invasive approach and avoids the complexities of the blood–brain barrier (BBB) penetration, validated both in vitro and in vivo; and a nanoparticle-based approach with GLS1-targeting dendriplexes (polyurea dendrimers) that cross the BBB and provide a targeted strategy to directly impair metabolic pathways within GBM cells.

These approaches offer a novel and promising direction for GBM therapy, proving that taking advantage of metabolic vulnerabilities favors the development of new therapeutic strategies for GBM. This thesis also emphasizes the importance of personalized metabolic profiling and metabolism-targeted interventions to enhance clinical outcomes.

2. Did you encounter any difficulties in carrying out this research? If yes, how did you overcome them, and what strategies did you use to stay focused and motivated?

Yes, I encountered several challenges during my PhD, as is natural in a multidisciplinary project like this. Right in the beginning, there were a lot of restrictions because of the COVID-19 pandemic, which limited the hours in the lab.

One of the most significant was the development of in vivo models, which was only possible thanks to an excellent collaboration with a research group from ICVS-University of Minho. Moreover, the Pathological Anatomy unit at IPOLisboa was pivotal for histological processing.

Another challenge was handling the vast amount of metabolomics data, which required extensive time and effort to analyze and interpret, done in the CERMAX facilities at ITQB-NOVA. In addition, optimizing the nanoparticles and establishing our in vitro BBB model were technically demanding tasks, but they became feasible through close collaboration with experts from Instituto Superior Técnico and Instituto Ricardo Jorge (INSA).

To overcome these obstacles, we relied on teamwork and adaptability. Collaborating with specialists allowed me to access expertise beyond my own and to learn more in different areas.

The biggest motivator was to contribute to this field and ultimately improve the prognosis and quality of life for patients with this aggressive brain tumor.

3. As an author, what aspects of a journal do you value the most when choosing a journal in which to publish your academic work?

As an author, I value journals that ensure a rigorous yet constructive peer-review process, providing clear and helpful feedback that strengthens the quality of the work. I also appreciate timely responses from the editorial board, as this helps maintain the momentum of the research. Of course, the reputation and integrity of the journal are equally important, as they reflect the credibility of the published work. Visibility within the target research community is another key factor, since dissemination to the right audience maximizes scientific impact. Finally, I take note if the journal is open access, as it promotes accessibility, collaboration, and broader engagement with research findings.

4. What is your current research interest and how do you plan to continue building on your research in the future? What are your long-term career aspirations?

Brain tumors remain one of the most challenging cancers to treat, and I am motivated to contribute to uncovering new biological insights that can be translated into more effective therapies.

In the coming years, I plan to continue brain tumor research through a postdoctoral position. Connecting metabolism, microenvironment and even cancer neuroscience will give us a lot of clues in the following years for more therapeutic vulnerabilities.

5. How does it feel to receive this recognition for your work? Is there something you would like to express or someone you would like to thank the most?

It is with great honor that I receive this award! This recognition holds a very special meaning, especially at such an early stage of my scientific career. It represents not only the acknowledgment of four years of intense work and dedication, but also the validation of the impact and excellence of the research carried out at IPO Lisboa and NOVA Medical School – Faculty of Medical Sciences.

Above all, this award is a reflection of the collective effort of everyone who was part of this project. A very special thank you to my PhD supervisors, Jacinta Serpa, Luís Gonçalves, and Marta Pojo, who guided me through the years. Thank you to the Cancer, Metabolism, and Microenvironment team at IPO Lisboa and NOVA Medical School – Faculty of Medical Sciences, to all my colleagues at UIPM, and to all collaborators who contributed to this work. Many thanks to all of you for being part of this achievement!

Conference: 38th Annual Congress of the European Association of Nuclear Medicine
Date: 4–8 October 2025
Location: Barcelona, Spain

We are pleased to announce that MDPI will participate in the 38th Annual Congress of the European Association of Nuclear Medicine (EANM25), to be held in Barcelona, Spain, from 4 to 8 October 2025.

One of the highlights of this year’s congress will be the continued focus on novel advances in theranostics. This rapidly evolving field continues to revolutionize our approach to diagnosis and treatment, offering unprecedented precision and personalized care for our patients. We have an exciting program lined up, featuring leading experts who will share their insights and latest research findings.

MDPI is excited to participate in this prestigious event! Representing the journal Diagnostics (ISSN: 2075-4418), Ms. Florina Maria Muresan and Ms. Lassie Shu will be present at the MDPI exhibition stand, where they will warmly welcome all scholars to stop by and engage in insightful discussions. This event presents a unique opportunity for participants to interact with leading experts in the field and explore potential collaborations. Do not miss the chance to visit our stand and exchange ideas with the MDPI editors and other delegates!

The following MDPI journals will be represented at the conference:

• Diagnostics;
• Diseases;
• Cancers;
• JCM;
• JPM;
• Medical Sciences;
• Tomography;
• Medicina;
• J. Imaging;
• Current Oncology;
• Uro.

If you are planning to attend the conference, please feel free to start a conversation with us. We invite all conference attendees to visit MDPI’s booth and meet with our esteemed Editorial Board Members.

For more information about the conference, please visit the following website: https://eanm25.eanm.org/.

September is “Gynecologic Cancer Awareness Month”, and various global activities are aiming to highlight and increase the awareness of gynecologic cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of gynecologic cancer, which were published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

“Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment”
by Holly Baker-Rand and Sarah J. Kitson
Cancers 2024, 16(5),1028; https://doi.org/10.3390/cancers16051028
Available online: https://www.mdpi.com/2072-6694/16/5/1028

“Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions”
by Rohan Kalyan Rej, Joyeeta Roy and Srinivasa Rao Allu
Cancers 2024, 16(3), 552; https://doi.org/10.3390/cancers16030552
Available online: https://www.mdpi.com/2072-6694/16/3/552

“Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer”
by Niraj Neupane, Sawyer Bawek, Sayuri Gurusinghe, Elham Moases Ghaffary, Omid Mirmosayyeb, Sangharsha Thapa, Carla Falkson, Ruth O’Regan and Ajay Dhakal
Cancers 2024, 16(3), 619; https://doi.org/10.3390/cancers16030619
Available online: https://www.mdpi.com/2072-6694/16/3/619

“Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer”
by Brittney S. Zimmerman and Francisco J. Esteva
Cancers 2024, 16(4), 800; https://doi.org/10.3390/cancers16040800
Available online: https://www.mdpi.com/2072-6694/16/4/800

“Gender-Specific Genetic Predisposition to Breast Cancer: BRCA Genes and Beyond”
by Virginia Valentini, Agostino Bucalo, Giulia Conti, Ludovica Celli, Virginia Porzio, Carlo Capalbo, Valentina Silvestri and Laura Ottini
Cancers 2024, 16(3), 579; https://doi.org/10.3390/cancers16030579
Available online: https://www.mdpi.com/2072-6694/16/3/579

“PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer”
by Nicholas Hirschl, Wildnese Leveque, Julia Granitto, Valia Sammarco, Mervyns Fontillas and Richard T. Penson
Cancers 2024, 16(5), 932; https://doi.org/10.3390/cancers16050932
Available online: https://www.mdpi.com/2072-6694/16/5/932

“Ensemble Deep Learning-Based Image Classification for Breast Cancer Subtype and Invasiveness Diagnosis from Whole Slide Image Histopathology”
by Aadhi Aadhavan Balasubramanian, Salah Mohammed Awad Al-Heejawi, Akarsh Singh, Anne Breggia, Bilal Ahmad, Robert Christman, Stephen T. Ryan and Saeed Amal
Cancers 2024, 16(12), 2222; https://doi.org/10.3390/cancers16122222
Available online: https://www.mdpi.com/2072-6694/16/12/2222

“Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis”
by Michela Roberto, Giacomo Barchiesi, Blerina Resuli, Monica Verrico, Iolanda Speranza, Leonardo Cristofani, Federica Pediconi, Federica Tomao, Andrea Botticelli and Daniele Santini
Cancers 2024, 16(3), 596; https://doi.org/10.3390/cancers16030596
Available online: https://www.mdpi.com/2072-6694/16/3/596

“Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer”
by Iseult M.Browne and Alicia F. C. Okines
Cancers 2024, 16(12), 2259; https://doi.org/10.3390/cancers16122259
Available online: https://www.mdpi.com/2072-6694/16/12/2259

“The Impact of Different Patterns of Residual Disease on Long-Term Oncological Outcomes in Breast Cancer Patients Treated with Neo-Adjuvant Chemotherapy”
by Corrado Tinterri, Bethania Fernandes, Alberto Zambelli, Andrea Sagona, Erika Barbieri, Simone Di Maria Grimaldi, Shadya Sara Darwish, Flavia Jacobs, Camilla De Carlo, Martina Iuzzolino et al.
Cancers 2024, 16(2), 376; https://doi.org/10.3390/cancers16020376
Available online: https://www.mdpi.com/2072-6694/16/2/376

You are welcome to submit relevant papers to the journal Cancers using the link below.
https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

Date: 23 September 2025
Time: 11:00 a.m.–4:30 p.m
Location: The Chelsea Hotel, 33 Gerrard Street West, Toronto

MDPI is thrilled to announce our participation in the University of Toronto’s largest career fair, taking place at the St. George Downtown Campus. This exciting event brings together thousands of students, graduates, and professionals looking to connect with top employers and explore career opportunities.

We invite all attendees to visit the MDPI booth to discover how you can be part of one of the world’s leading open access academic publishers. Whether you are passionate about scientific research, editorial work, marketing, or supporting global innovation in publishing, we want to meet YOU!

What to expect at our booth:

• Learn more about MDPI’s mission and global impact;
• Explore exciting career opportunities in publishing, editorial, communications, and more;
• Network with our team and ask questions about working at MDPI.

Whether you’re just starting your career or looking to take the next step, don’t miss this opportunity to connect with MDPI. Bring your resume, your curiosity, and your questions—we look forward to seeing you there!

For additional information on the Career Fair and Open MDPI positions, please visit the following links:

• Learn more about the U of T Career Fair;
• Explore Careers with MDPI Canada.

Conference: 2025 International Conference of the Korean Society for Molecular and Cellular Biology (KSMCB 2025)
Booth Number: 72
Date: 29 September–2 October 2025
Location: ICC Jeju, Jeju Island, Republic of Korea

The Korean Society for Molecular and Cellular Biology (KSMCB) was founded in 1988 and has expanded to become one of the largest and most prominent academic societies in the field of life sciences in Korea. The KSMCB aims to advance research, communication, collaboration, and education in the field of biological sciences, from fundamental molecular biology to biomedical and agricultural research. The programs featured in the ICKSMCB offer a platform to cultivate bioscience research and disseminate scientific discoveries, cutting-edge information, and innovative ideas.

MDPI will be attending the 2025 International Conference of the KSMCB (ICKSMCB) as an exhibitor. This event will be held from 29 September to 2 October, and we welcome all researchers to visit our booth and discuss their latest research with us.

The following MDPI journals will be represented at the conference:

• Life;
• Sci;
• Biophysica;
• Cells;
• Biologics;
• BioMed;
• Biomedicines;
• Biomolecules;
• BioTech;
• Cancers;
• Current Issues in Molecular Biology;
• Genes;
• International Journal of Molecular Sciences;
• Metabolites;
• Microorganisms;
• Non-Coding RNA;
• Plants.

Our delegates look forward to meeting you in person at our booth and answering any questions you may have. For more information regarding this conference, please visit the following website: https://www.ksmcb.or.kr/icksmcb2025/main.html.

We are pleased to announce that four new scholars have been appointed as Editorial Board Members (EBMs) of Cancers (ISSN: 2072-6694), joining in August 2025. We wish our new members success in both their research and their efforts to develop the journal.

Name: Prof. Dr. Ithaar H. Derweesh
Affiliation: Department of Urology, UC San Diego Health System, San Diego, CA 92037, USA
Interests: renal cell carcinoma; nephrectomy; targeted molecular therapy; immunotherapy; upper tract urothelial carcinoma; nephroureterectomy; chronic renal insufficiency; urologic oncology

Name: Dr. Fedro Alessandro Peccatori
Affiliation: Fertility and Procreation Unit, Gynecologic Oncology Department, IRCCS European Institute of Oncology (IEO), European School of Oncology (ESO), 20141 Milan, Italy
Interests: cancer in pregnancy; survivorship care; fertility preservation; oncofertility; breast cancer; ovarian cancer; non epithelial ovarian cancer; cancer in adolescents and young adults

Name: Dr. Yoo-Seok Yoon
Affiliation: Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul 13620, Republic of Korea
Interests: pancreato-biliary surgery; minimally invasive surgery; pancreatic cancer; gallbladder cancer; extrahepatic bile duct cancer

Name: Prof. Dr. Peter F. Ehrlich
Affiliation: Section of Pediatric Surgery, Department of Surgery, C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, MI, USA
Interests: pediatrics; tumor; renal tumors in children, especially Wilms' Tumor

Further details about the Editorial Board of Cancers can be found by clicking the following link: https://www.mdpi.com/journal/cancers/editors.

Cancers is recruiting scholars from around the world to join our Editorial Board.

• A full academic CV;
• A short cover letter detailing your interest in the position.